Dulaglutide vs BI 456906
Head-to-head comparison of Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Dulaglutide | BI 456906 |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Recombinant GLP-1 receptor agonist Fc fusion protein | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | ~63,000 Da | N/A |
| Half-Life | About 5 days | Approximately 1 week |
| Amino Acids | N/A | N/A |
| Typical Dose | 0.75-4.5 mg weekly | Trial-dependent; weekly SC dosing |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 700 | 10 |
| Research Status | Approved | Clinical |
Dulaglutide Benefits
- ✓modest weight loss
- ✓lower A1c
- ✓weekly dosing convenience
- ✓cardiometabolic benefit
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Dulaglutide Dosing
0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Dulaglutide Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠injection-site reactions
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
Dulaglutide
Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.